Janssen (Johnson & Johnson) Must Pay $70 Million In Risperdal Case
- 8 years ago
A U.S. jury on Friday awarded $70 million to the family of a boy who developed breasts after taking Johnson & Johnson unit Janssen Pharmaceuticals' antipsychotic drug Risperdal. The jury in the Philadelphia Court of Common Pleas found that the company failed to warn the boy's healthcare providers about the risk of gynecomastia and that it intentionally falsified, destroyed, or concealed evidence in the case.